<i>Clostridioides difficile</i> Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis

• Main Authors: Alice Annalisa Medaglia (Author), Alessandro Mancuso (Author), Chiara Albano (Author), Giuseppe Zinna (Author), Luca Pipitò (Author), Cinzia Calà (Author), Rita Immordino (Author), Raffaella Rubino (Author), Silvia Bonura (Author), Baldassare Canino (Author), Giuseppe Calamusa (Author), Claudia Colomba (Author), Pier Luigi Almasio (Author), Antonio Cascio (Author)
• Format: Book
• Published: MDPI AG, 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/antibiotics12050837; 2079-6382
• Keywords: <i>Clostridioides difficile</i> infection; fidaxomicin; vancomycin; metronidazole; bezlotoxumab; hemodialysis; Therapeutics. Pharmacology; RM1-950
• Source: Antibiotics, Vol 12, Iss 5, p 837 (2023)

<i>Clostridioides difficile</i> infection (CDI) is a significant cause of morbidity and mortality, mostly in frail patients. Notification is not mandatory in Italy, and data on incidence, risk of death, and recurrence are lacking. The purpose of this study was to determine CDI incidence and risk factors for mortality and recurrence. The "ICD-9 00845" code in hospital-standardized discharged forms (H-SDF) and microbiology datasets were used to retrieve CDI cases at Policlinico Hospital, Palermo between 2013 and 2022. Incidence, ward distribution, recurrence rate, mortality, and coding rate were considered. The risk of death and recurrence was predicted through multivariable analysis. There were 275 CDIs, 75% hospital-acquired, the median time between admission and diagnosis was 13 days, and the median stay was 21 days. Incidence increased from 0.3 to 5.6% (an 18.7-fold increase) throughout the decade. Only 48.1% of cases were coded in H-SDF. The rate of severe/severe-complicated cases increased 1.9 times. Fidaxomicin was used in 17.1% and 24.7% of cases overall and since 2019. Overall and attributable mortalities were 11.3% and 4.7%, respectively. Median time between diagnosis and death was 11 days, and recurrence rate was 4%. Bezlotoxumab was administered in 64% of recurrences. Multivariable analysis revealed that only hemodialysis was associated with mortality. No statistically significant association in predicting recurrence risk emerged. We advocate for CDI notification to become mandatory and recommend coding CDI diagnosis in H-SDF to aid in infection rate monitoring. Maximum attention should be paid to preventing people on hemodialysis from getting CDI.